In addition, patients with BRAF V600-mutated melanoma, elevated LDH, and brain metastases have been shown to draw a higher magnitude of benefit in survival from combination ICI in comparison to anti-PD-1 monotherapy based on subgroup analyses of the CheckMate 067 study [5,34]. The gene discussed is BRAF; the disease is melanoma.